<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02728245</url>
  </required_header>
  <id_info>
    <org_study_id>SNUBH_GO_052</org_study_id>
    <nct_id>NCT02728245</nct_id>
  </id_info>
  <brief_title>Trial Comparing Preoperative Dienogest Therapy Followed by Surgery vs. Upfront Surgery to Save Ovarian Reserve in Young Women With Ovarian Endometrioma</brief_title>
  <acronym>DOROSY</acronym>
  <official_title>Randomized Phase 2 Trial Comparing Preoperative Dienogest Therapy Followed by Surgery vs. Upfront Surgery to Save Ovarian Reserve in Young Women With Ovarian Endometrioma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Kyung Hee University Hospital at Gangdong</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Korea University Guro Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ajou University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ewha Womans University Mokdong Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Asan Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Randomized phase 2 trial comparing preoperative dienogest therapy followed by surgery vs.
      upfront surgery to save ovarian reserve in young women with ovarian endometrioma
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Placebo cannot be prepared
  </why_stopped>
  <start_date type="Anticipated">October 2017</start_date>
  <completion_date type="Anticipated">March 2018</completion_date>
  <primary_completion_date type="Anticipated">March 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Compare the mean change of serum Anti-Mullerian Hormone (AMH) level</measure>
    <time_frame>3 month after surgery</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Compare the mean change of serum AMH level</measure>
    <time_frame>1 month after surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare the trend of mean change of serum AMH level</measure>
    <time_frame>1 and 3 month after surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare the mean change of serum AMH level</measure>
    <time_frame>baseline and after preoperative dienogest/placebo therapy for 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare the revised American fertility society (AFS) score</measure>
    <time_frame>At surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>compare the surgical time (minute)</measure>
    <time_frame>intraoperative</time_frame>
    <description>surgical time (minute)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Brief Pain Inventory (BPI) scores</measure>
    <time_frame>baseline, 1 month after surgery and 3 month after surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of participants with treatment-related adverse events as assessed by CTCAE v4.0</measure>
    <time_frame>All adverse events from randomization to postoperative 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change of diameter of endometrioma measured by ultrasonography after preoperative dienogest/placebo therapy for 3months</measure>
    <time_frame>baseline and after preoperative dienogest/placebo therapy for 3 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Ovarian Reserve</condition>
  <condition>Endometriosis</condition>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo drug 1 tablet per day will be prescribed for 3months before surgery in ovarian endometrioma patients.
Dienogest(DNG) 2mg 1 tablet per day will be prescribed for 2 months from 1month after surgery.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Case group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dienogest(DNG) 2mg 1 tablet per day will be prescribed for 3months before surgery in ovarian endometrioma patients.
Dienogest(DNG) 2mg 1 tablet per day will be prescribed for 2 months from 1month after surgery.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dienogest</intervention_name>
    <description>Dienogest 2mg po qd</description>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_label>Case group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo drug</intervention_name>
    <description>Placebo 1 table po qd</description>
    <arm_group_label>Control group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Surgery</intervention_name>
    <description>conservative surgery without intent to oophorectomy</description>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_label>Case group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Unilateral ovarian endometrioma ≥ 5cm or bilateral ovarian endometriomas with any size
             diagnosed by ultrasonography.

          -  In Patients with previous unilateral salpingo-oophorectomy (USO)

          -  Unilateral ovarian endometrioma with any size is eligible

          -  20 ≤ Age ≤ 45 and premenopause

          -  Plan to undergo conservative surgery for endometriomas

        Exclusion Criteria:

          -  Pregnant women or women who were suspected to be pregnant

          -  Women with current venous thromboembolism or history of such diseases

          -  Women with current arterial disease or cardiovascular diseases (e.g. myocardial
             infarction, cerebrovascular diseases, or ischemic heart diseases) or history of such
             diseases

          -  Women with current diabetes with vascular lesions or history of such diseases

          -  Women with current severe liver diseases or history of severe liver diseases with
             abnormal liver function

          -  Women with current liver tumor or history of liver tumor

          -  Women with current or history of sex-hormone dependent malignant tumor or women who
             were suspected to have a sex-hormone dependent malignant tumor

          -  Women with vaginal bleeding of unknown causes

          -  Women with a history of allergic reaction to elements of DNG

          -  Women with galactose intolerance, Lapp lactase deficiency, glucose-galactose
             malabsorption

          -  Women whose non-compliance is expected

          -  Lactation (treatment with DNG is not recommended in lactating women due to possible
             excretion in breast milk)

          -  Any medication that could result in an excessive accumulation, impaired metabolism, or
             altered excretion of the study drug or might interfere with the conduct of the study
             or the interpretation of the results
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Seoul National University Bundang Hospital</name>
      <address>
        <city>Seongnam Si</city>
        <state>Gyeonggi Do</state>
        <zip>463707</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 19, 2016</study_first_submitted>
  <study_first_submitted_qc>March 30, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 5, 2016</study_first_posted>
  <last_update_submitted>October 28, 2017</last_update_submitted>
  <last_update_submitted_qc>October 28, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 31, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seoul National University Hospital</investigator_affiliation>
    <investigator_full_name>Kidong Kim</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Endometriosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dienogest</mesh_term>
    <mesh_term>Nandrolone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

